Fox Run Management, L.L.C. Cti Biopharma Corp Transaction History

Fox Run Management, L.L.C.

  • $433 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 07, 2022
BUY
$5.36 - $7.43 $103,249 - $143,124
19,263 New
19,263 $112,000

About CTI BIOPHARMA CORP

CTIC Quotes by TradingView
  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email